Evonik Shareholders Face Dividend Cut Amid Restructuring

Evonik reduces dividend to €1.00 per share, launches €400M cost program cutting 2,000 jobs, as revenue falls and ROCE misses target. Share price down 37% in a year.

Investors in Evonik are feeling the direct financial impact of the specialty chemicals group's ongoing transformation. The Essen-based company, while having met its formal profit targets for the past year, is now implementing a stricter dividend policy as it navigates a challenging market environment and a significant cost-cutting program.

Financial Performance and Strategic Shift

The company's latest figures highlight persistent headwinds. Revenue declined by 7% year-on-year to €14.1 billion, pressured by elevated energy costs and subdued demand. Although adjusted EBITDA landed precisely within its forecasted range at €1.87 billion, the return on capital employed (ROCE) of 6.1% remains substantially below the firm's medium-term target of 11%.

This operational backdrop has led to immediate consequences for shareholder returns. The dividend for the 2025 fiscal year will be reduced to €1.00 per share, a noticeable drop from the previous €1.17. Furthermore, Evonik has announced a new, more disciplined framework for future distributions. Beginning in 2026, the payout will be directly linked to adjusted net income, with a policy to distribute between 40% and 60% to shareholders.

Cost-Cutting Drive to Restore Profitability

To improve profitability, management is enacting a rigorous savings plan. The "Evonik Tailor Made" transformation program aims to achieve annual cost reductions of approximately €400 million by 2026. This restructuring comes at a significant human cost, with up to 2,000 positions slated for elimination worldwide, the majority of which are in Germany.

The combination of this extensive overhaul and the reduced dividend has unsettled the market. Evonik's share price remains under pressure, closing Friday's session at €13.82, down 1.64%. The stock's downward trend over the past year is pronounced, showing a loss of nearly 37%.

Cautious Guidance and Upcoming Milestones

The outlook for the current year is clouded by uncertainty. The company has provided guidance for adjusted EBITDA between €1.7 billion and €2.0 billion, a wide range that underscores the volatility of current market conditions. A minor positive special effect could arise from potential tariff reimbursements in the United States following a court ruling, which might amount to a figure in the tens of millions.

Investors are now looking ahead to two key dates. The next important milestone will be May 8, when Evonik releases its first-quarter 2026 results. This report will be scrutinized for early signs that the aggressive cost-saving measures are taking effect. Subsequently, shareholders will vote on the new dividend policy at the Annual General Meeting scheduled for June 3.